Role of cholinesterase inhibitors in Parkinson's disease and dementia with Lewy bodies (Q35863422)

10 August 2017

1 reference

title

Role of cholinesterase inhibitors in Parkinson's disease and dementia with Lewy bodies (English)

1 reference

10 August 2017

0 references

1 reference

1

Dag Aarsland

1 reference

10 August 2017

0 references

Urs P Mosimann

2

1 reference

10 August 2017

Ian G McKeith

series ordinal

3

1 reference

10 August 2017

language of work or name

1 reference

1 September 2004

1 reference

Journal of Geriatric Psychiatry and Neurology

10 August 2017

1 reference

10 August 2017

17

1 reference

10 August 2017

3

1 reference

10 August 2017

164-171

1 reference

Basal forebrain neurons in the dementia of Parkinson disease

10 August 2017

1 reference

https://api.crossref.org/works/10.1177%2F0891988704267463

Dementia with Lewy bodies: choline acetyltransferase parallels nucleus basalis pathology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0891988704267463

Cholinergic correlates of cognitive impairment in Parkinson's disease: comparisons with Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0891988704267463

Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0891988704267463

Comparative alterations of nicotinic and muscarinic binding sites in Alzheimer's and Parkinson's diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0891988704267463

The decline in synapses and cholinergic activity is asynchronous in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0891988704267463

Early and widespread cholinergic losses differentiate dementia with Lewy bodies from Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0891988704267463

In vivo mapping of cholinergic terminals in normal aging, Alzheimer's disease, and Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0891988704267463

Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0891988704267463

The pedunculopontine nucleus in Parkinson's disease, progressive supranuclear palsy and Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0891988704267463

Synucleinopathy pathology and REM sleep behavior disorder plus dementia or parkinsonism

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0891988704267463

Evidence of a Monoaminergic-Cholinergic Imbalance Related to Visual Hallucinations in Lewy Body Dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0891988704267463

Nicotine binding in human striatum: elevation in schizophrenia and reductions in dementia with Lewy bodies, Parkinson's disease and Alzheimer's disease and in relation to neuroleptic medication.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0891988704267463

Extrapyramidal features in Parkinson's disease with and without dementia and dementia with Lewy bodies: A cross-sectional comparative study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0891988704267463

Pathology and neurotransmitter abnormalities of dementia with Lewy bodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0891988704267463

Advances in the treatment of Alzheimer's disease: benefits of dual cholinesterase inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0891988704267463

Regulation of attention and response to therapy in dementia by butyrylcholinesterase

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0891988704267463

Butyrylcholinesterase and progression of cognitive deficits in dementia with Lewy bodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0891988704267463

Acetyl- and butyrylcholinesterase activity in the cerebrospinal fluid of patients with Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0891988704267463

Nicotinic receptor losses in dementia with Lewy bodies: comparisons with Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0891988704267463

Nicotinic acetylcholine receptor distribution in Alzheimer's disease, dementia with Lewy bodies, Parkinson's disease, and vascular dementia: in vitro binding study using 5-[(125)i]-a-85380.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0891988704267463

Visual hallucinations are associated with lower alpha bungarotoxin binding in dementia with Lewy bodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0891988704267463

Disturbances of consciousness in dementia with Lewy bodies associated with alteration in nicotinic receptor binding in the temporal cortex.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0891988704267463

Nicotine may relieve symptoms of Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0891988704267463

Transdermal nicotine in PD: a randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0891988704267463

Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0891988704267463

Donepezil for cognitive impairment in Parkinson's disease: a randomised controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0891988704267463

Randomized placebo-controlled trial of donepezil in cognitive impairment in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0891988704267463

Donepezil in the treatment of hallucinations and delusions in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0891988704267463

Cognitive, psychiatric and motor response to galantamine in Parkinson's disease with dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0891988704267463

Acetylcholinesterase inhibition in dementia with Lewy bodies: results of a prospective pilot trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0891988704267463

Efficacy and safety of galantamine in patients with dementia with Lewy bodies: a 12-week interim analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0891988704267463

Rivastigmine in the treatment of dementia with Lewy bodies: preliminary findings from an open trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0891988704267463

Severe worsening of parkinsonism in Lewy body dementia due to donepezil

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0891988704267463

Cerebral atrophy in Parkinson's disease with and without dementia: a comparison with Alzheimer's disease, dementia with Lewy bodies and controls.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0891988704267463

Muscarinic receptors in basal ganglia in dementia with Lewy bodies, Parkinson's disease and Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0891988704267463

Better cognitive and psychopathologic response to donepezil in patients prospectively diagnosed as dementia with Lewy bodies: a preliminary study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0891988704267463

Lewy bodies and response to tacrine in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0891988704267463

Increased Alzheimer pathology in Parkinson's disease related to antimuscarinic drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0891988704267463

What happens when donepezil is suddenly withdrawn? An open label trial in dementia with Lewy bodies and Parkinson's disease with dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0891988704267463

Chronic effects of dopaminergic replacement on cognitive function in Parkinson's disease: a two-year follow-up study of previously untreated patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0891988704267463

Neuroleptic sensitivity in patients with senile dementia of Lewy body type

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0891988704267463

The beneficial effect of donepezil on visual hallucinations in three patients with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0891988704267463

Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: preliminary findings from an open trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0891988704267463

Successful use of donepezil for the treatment of psychotic symptoms in patients with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0891988704267463

Rivastigmine for the treatment of dementia and visual hallucinations associated with Parkinson's disease: a case series

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0891988704267463

Rivastigmine (Exelon) for dementia in patients with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0891988704267463

The beneficial effect of cholinesterase inhibitors on patients suffering from Parkinson's disease and dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0891988704267463

Effects of rivastigmine on cognitive function in dementia with lewy bodies: a randomised placebo-controlled international study using the cognitive drug research computerised assessment system

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0891988704267463

21 January 2018

Identifiers

DOI

10.1177/0891988704267463

1 reference

release_6nwhjnjo55f35aoftjo5l2lxd4

10 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/6nwhjnjo55f35aoftjo5l2lxd4

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference